G6PD variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19
View ORCID ProfileJorge da Rocha, View ORCID ProfileHoucemeddine Othman, View ORCID ProfileCaroline T. Tiemessen, View ORCID ProfileGerrit Botha, View ORCID ProfileMichèle Ramsay, View ORCID ProfileCollen Masimirembwa, View ORCID ProfileClement Adebamowo, View ORCID ProfileAnanyo Choudhury, View ORCID ProfileJean-Tristan Brandenburg, View ORCID ProfileMogomotsi Matshaba, View ORCID ProfileGustave Simo, View ORCID ProfileFrancisco-Javier Gamo, View ORCID ProfileScott Hazelhurst, as members of the H3Africa Consortium
doi: https://doi.org/10.1101/2020.05.27.20114066
Jorge da Rocha
1Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
2Division of Human Genetics, National Health Laboratory Service, and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Houcemeddine Othman
1Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Caroline T. Tiemessen
3Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg South Africa
Gerrit Botha
4Computational Biology Division and H3ABioNet, Department of Integrative Biomedical Sciences, University of Cape Town, South Africa
Michèle Ramsay
1Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
2Division of Human Genetics, National Health Laboratory Service, and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Collen Masimirembwa
1Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Clement Adebamowo
5Institute for Human Virology, Abuja, Nigeria
6Institute of Human Virology and Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD
Ananyo Choudhury
1Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Jean-Tristan Brandenburg
1Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Mogomotsi Matshaba
8Botswana-Baylor Children’s Clinical Center of Excellence, Gaborone, Botswana
9Baylor College of Medicine, Houston, United States
Gustave Simo
7Molecular Parasitology and Entomology Unit, Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon
Francisco-Javier Gamo
10Global Health, GlaxoSmithKline R&D, Madrid, Spain
Scott Hazelhurst
11School of Electrical & Information Engineering, University of the Witwatersrand, Johannesburg, South Africa
1Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Data Availability
Datasets used in this study were generated as part of the Human Heredity and Health in Africa Project (H3Africa). H3Africa is committed submit these datasets to the European Genome-Phenome Archive (EGA), where access can be obtained through the H3Africa Data and Biospecimen Access Committee.
Posted June 02, 2020.
G6PD variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19
Jorge da Rocha, Houcemeddine Othman, Caroline T. Tiemessen, Gerrit Botha, Michèle Ramsay, Collen Masimirembwa, Clement Adebamowo, Ananyo Choudhury, Jean-Tristan Brandenburg, Mogomotsi Matshaba, Gustave Simo, Francisco-Javier Gamo, Scott Hazelhurst, as members of the H3Africa Consortium
medRxiv 2020.05.27.20114066; doi: https://doi.org/10.1101/2020.05.27.20114066
G6PD variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19
Jorge da Rocha, Houcemeddine Othman, Caroline T. Tiemessen, Gerrit Botha, Michèle Ramsay, Collen Masimirembwa, Clement Adebamowo, Ananyo Choudhury, Jean-Tristan Brandenburg, Mogomotsi Matshaba, Gustave Simo, Francisco-Javier Gamo, Scott Hazelhurst, as members of the H3Africa Consortium
medRxiv 2020.05.27.20114066; doi: https://doi.org/10.1101/2020.05.27.20114066
Subject Area
Subject Areas
- Addiction Medicine (357)
- Allergy and Immunology (681)
- Anesthesia (182)
- Cardiovascular Medicine (2694)
- Dermatology (229)
- Emergency Medicine (405)
- Epidemiology (12333)
- Forensic Medicine (10)
- Gastroenterology (773)
- Genetic and Genomic Medicine (4170)
- Geriatric Medicine (393)
- Health Economics (689)
- Health Informatics (2703)
- Health Policy (1010)
- Hematology (366)
- HIV/AIDS (864)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (446)
- Neurology (3953)
- Nursing (214)
- Nutrition (587)
- Oncology (2084)
- Ophthalmology (596)
- Orthopedics (245)
- Otolaryngology (308)
- Pain Medicine (254)
- Palliative Medicine (75)
- Pathology (474)
- Pediatrics (1134)
- Primary Care Research (462)
- Public and Global Health (6593)
- Radiology and Imaging (1430)
- Respiratory Medicine (879)
- Rheumatology (416)
- Sports Medicine (345)
- Surgery (456)
- Toxicology (56)
- Transplantation (191)
- Urology (170)